CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS

Summary

Approximately 21 subjects with amyotrophic lateral sclerosis (ALS) will be randomized (6 to 1) to receive by mouth seven morning doses of CC100 or placebo for 7 days. Subjects are required to stay in the Clinic for approximately 9 hours following the first and last dose. Subjects will also have a mid-week clinic visit and will be contacted by phone within 3 to 5 days after the last dose. Funding Source - FDA OOPD

Timeline

Start

2017-04-07

Primary completion

2018-01-30

Completion

2018-03-30

Drugs

Indications